HealthTree Logo
search more_vert
person Sign In / Create Account
Clinical Trial CAR T Coverage for Medicare/Medicaid Multiple Myeloma Patients Proposed
Posted: Feb 19, 2019
Clinical Trial CAR T Coverage for Medicare/Medicaid Multiple Myeloma Patients Proposed image

On February 15, the Centers for Medicare & Medicaid Services (CMS) announced a proposal to cover chimeric antigen receptor (CAR) T-cell therapy for cancer patients who are participating in clinical trials that study treatment effectiveness.

This proposal would require CMS to cover nationwide CAR T-cell therapies "when the treatment is offered in CMS-approved registries or clinical studies in which patients are monitored for 2 or more years following treatment."

“Today’s proposed coverage decision would improve access to this [CAR T-cell] therapy while deepening CMS’s understanding of how patients in Medicare respond to it, so the agency can ensure that it is paying for CAR T-cell therapy for cases in which the benefits outweigh the risks.” --CMS Administrator Seema Verma

A final decision to the proposal is expected May of 2019.

This is incredibly hopeful for myeloma patients as many are on Medicare/Medicaid. We look forward to this coverage approval and it can't come soon enough for patients enrolling on CAR T studies. 


Read the full article.

Read the proposal summary.


The author Erika Johnson

about the author
Erika Johnson

Myeloma Crowd Editorial Contributor, Nursing student, and cancer advocate.

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Bristol Myers Squibb

Follow Us

facebook instagram linkedin tiktok youtube